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Currently, the goal of testing for RBC antibodies is to use a method
that will detect, if possible, all antibodies that are considered
clinically significant and yet not detect antibodies of little clinical
importance in transfusion or pregnancy. The focus of test method
development has been on the more controllable variables of the
first and second stages of agglutination. Tube test methods have
been developed over the years to achieve shorter turnaround times
for quicker test results and improved sensitivity,with the occasional
negative impact on relevant results. The focus on improving
efficiency through automation, and personnel resourcing
challenges of the transfusion service, have led laboratories to select
methods tailored to meet their needs. This review compares the
newer methods used in the gel test and solid phase test with
commonly used tube methods. Both of the newer methods were
developed with future adaptation to automation in mind. Further
literature reviews about antibodies detected in only one or two
methods and their general lack of clinical relevance as well as the
occasional rare examples that produce significant clinical effects on
transfused patients are also discussed. Immunohematology
2006;22:196–202.
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The challenge of being able to detect only clinically
significant antibodies (wanted) but not detect those
antibodies that have no clinical importance
(unwanted) has long been the desire of the
immunohematologist. In today’s talent- and resource-
strained environment, there is an expectation that this
perfect antibody screening test exists. Judd1 et al. have
previously described the concept of wanted and
unwanted specificities of antibodies detected in a
comparison of the LISS tube test with the gel method
(ID-Micro Typing Systems Gel Test, Ortho-Clinical
Diagnostics, Raritan,NJ). The categories of wanted and
unwanted antibodies are based on the specificity of the
antibody as it relates to past experience with its ability
to cause or have the potential to cause adverse
transfusion events or hemolytic disease of the newborn
and fetus. Table 1 shows those specificities that
compose these respective categories.
Approaches to improving antibody screen test
sensitivity and specificity relate to the ability to
manipulate and control important variables in the first
stage of agglutination (antigen concentration,
temperature, incubation time, ionic strength, and pH)
and, if possible, to affect certain aspects of the second
stage of agglutination. The out-of-our-control variables
are the antibody equilibrium constant (affinity) and the
chemical bonding characteristics of the antigen and
antibody.
Over time, new methods and reagents introduced
with the intent to increase sensitivity have sometimes
resulted in decreased specificity.2
Methods of Testing
Tube test methods
Tube test methods have been the long-standing
method for antibody screening since before the
introduction of newer technologies for antibody
detection, such as the gel test and solid phase testing.
Various methods, such as the use of saline with two
drops of serum, saline with increased serum-to-cell
ratios (4–8 drops of serum to 1 drop of 2-4% reagent
RBCs); bovine serum albumin (BSA) (22%, 30%, and
polymerized); LISS RBC suspension and LISS-additive
methods; polybrene; PEG and PEG-LISS additive
In search of the Holy Grail:
comparison of antibody screening
methods
T.S. CASINA







Other blood group antibodies Anti-D (passively acquired)
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methods; and proteolytic enzymes (ficin, papain,
bromelin, etc.) have been used for antibody detection,
some more effectively than others. Because of the
effect of enzymes on certain RBC antigens, an enzyme
method cannot be solely used for antibody screening
and identification.
The saline tube test is easy to use and low in cost,
but has poor sensitivity, particularly when used in
protocols with shorter incubation times. Because the
long incubation required to achieve good sensitivity
conflicts with the need to provide blood and
components in faster timeframes, the routine use of
saline test methods has fallen to about 2 percent of
laboratories in the United States.3,4 BSA methods
contributed to an improvement in detection of
antibodies; mainly those that are direct agglutinating,
but only minimally improved the sensitivity of indirect
agglutinating antibodies. The BSA method continued
to be challenged because of the longer incubation
times needed to detect antibodies of the weaker
variety and its ability to detect unwanted reactivity.
Low and Messeter’s introduction of the low-ionic
strength saline method and the resultant LISS-based
additives that came to market contributed the first
significant improvement in antibody detection by
allowing an increased rate of antibody uptake in a shorter
timeframe.5 Additionally, these additives increased the
amount of antibody uptake. The specificity of both BSA
and LISS tests was made difficult by the use of
polyspecific antihuman globulin (AHG) reagents that
contributed to the detection of unwanted reactivity.
Switching to a monospecific antiglobuin reagent such as
anti-IgG improved specificity but produced a decrease in
sensitivity of the BSA test.2 A less frequently used
enhancement, polybrene, although quite popular with
the few laboratories that used it routinely, offered speed
and sensitivity but took some significant technique
adjustment for laboratorians to become proficient in
its use; therefore the test method never enjoyed much
popularity. During the 1980s, LISS-based methods
became increasingly popular;they remain today the most
frequently used tube test method for antibody detection.
In 1987, Nance and Garratty introduced PEG as a
new potentiator for the detection of RBC antigen-
antibody reactions.6 A PEG/LISS method using this
additive gained popularity as a routine antibody screen
method in some institutions and as a routine or adjunct
method for antibody identification in many others.
The use of proteolytic enzymes combined with
another method able to detect enzyme-sensitive
antibody specificities as a test for routine antibody
screen test never gained much favor in the United
States but could be found in routine use in some
provinces of Canada, some European and some Asian-
Pacific countries.7 The routine use of enzymes for
antibody screening has significantly decreased globally
with suggested changes in practice8,9; however,
enzymes have gained popularity for antibody
identification.
Gel test
The gel test (ID-Micro Typing System Gel Test,
Ortho-Clinical Diagnostics) was developed by Lapierre
and commercialized into a plastic card with six
microtubes containing dextran acrylamide gel with
antisera (specific antibody or AHG) or neutral
buffer.10,11 The principle of this test is based on the use
of gel to trap agglutinates. Measured volumes of RBCs
in a low-ionic environment are added to plasma in the
upper chamber of the microtubes. The gel cards are
incubated, if necessary, and centrifuged. Anti-IgG
contained in the gel microtube reacts with RBCs
sensitized with antibody, producing agglutination. The
gel traps the agglutinates, producing reactions that can
be graded from 1+ to 4+. The reactions are stable and
allow for the review of results for up to 24 hours after
testing is completed. RBCs can be prepared for testing
using a special RBC diluent,making the gel test flexible
for use with any selected RBC. The lack of a washing
step contributes to the sensitivity of the test.
Ultimately, these features made the gel test ideal for
automation.
Other column agglutination-based tests designed
on similar test principles are available outside of the
United States but are not discussed here.
Solid phase RBC adherence test
The solid phase RBC adherence test (SPRCA) was
developed in the early 1980s through the work of
Plapp et al.12 The principle of this test is based on the
ability of an antigen or antibody to be bound to the
solid matrix of a plastic microplate well. When the
appropriate reactant (antigen or antibody) is added to
the well, an antigen-antibody reaction occurs, resulting
in adherence of RBCs or tagged RBCs to the well. Two
different principles are used in the products
commercially available in the United States.
The Capture-R Ready test (ImmucorGamma,
Atlanta, GA) consists of a monolayer of RBC
membranes bound to the surface of a polystyrene
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microplate well. When serum or plasma and a LISS
additive are added to the well with the monolayer of
RBCs and incubated at 37°C, antibodies, if present, can
interact with the bound membrane antigens. After
washing to remove any unbound antibody, anti-IgG-
coated indicator RBCs are added to the microwell.
After centrifugation to allow interaction and binding of
indicator RBCs with antibody bound to the membrane,
a positive reaction is indicated by RBC adherence to
the well surface. A negative test is indicated by the
formation of a button of RBCs in the center of the
microwell.
The principle of the other SPRCA test (Solidscreen,
Biotest, Dreieich, Germany) follows the more
traditional approach of the standard IAT. Antibody
screen RBCs and serum or plasma are combined in a
low-ionic environment and allowed to incubate. After
washing to remove unbound antibody, anti-IgG is
added. The specially activated (treated) bottom of the
microwell allows RBCs sensitized with antibody and
anti-IgG to adhere, once centrifuged, to the microwell
via the Fc portion of the anti-IgG molecule.
The SPRCA tests are available in a microplate
format; the plate frame will hold from 1 to 12 strips of
8 microwells or individual strips of 8 microwells,
depending on the test system and automation used.
Both the gel test and the SPRCA test produce easily
defined endpoints that allowed for their transition to
an automated platform.
Transition to newer technologies
Overall, tube testing is considered to be the most
intensive of the procedures used for antibody
detection from the perspective of the number of steps
and trained personnel required to perform the test.
Generally, depending on the tube test method selected
and the phases of reactivity that a facility chooses to
perform, the number of procedural steps can range
from 14 to 19. For SPRCA testing, the number of steps
varies from 13 to 15 among the methods. Gel testing
can be completed in 8 steps using commercially
prepared RBCs and in up to 12 steps if RBC
suspensions need to be manually prepared.
Tube test reagents are generally lower in cost as
compared with the newer technologies. However,
overall costs associated with the skill required, hands-
on time, and non-value-added activity time are higher
with tube test methods. The transformation of
antibody detection test methods into newer
technologies and the innovation of automation
capability with these technologies have provided
transfusion services with a pathway to efficiency and
standardization with a well-balanced capability in
antibody detection testing. This new-found capability
along with the difficulty in finding experienced staff to
fill the ever-increasing vacancies have propelled
transfusion services to select tests and automation to
fill the gaps created by these challenges. The
automation of these methods has eliminated costs
linked to the human intervention and manipulation
required of tube tests.
Methods in Use
Table 2 shows the distribution of methods in use
for antibody screening based on the College of
American Pathologists Transfusion Medicine Survey for
antibody screen test method reporting.3,4 The data
clearly demonstrate the continued downward trend in
the use of saline and albumin tube test methods, with
LISS-based methods having the highest percentage of
usage at 37 percent among tube methods. Methods
that use newer technologies in manual-based systems
have increased substantially from 30 percent in 2001 to
47 percent in 2005. Additional information concerning
the usage of these technologies on automated
platforms can be obtained from the aforementioned
survey.
Performance Characteristics of Test Methods
As the antibody screen test became part of routine
pretransfusion testing, the approach was to detect all
antibodies with little regard to their relevance to
clinical importance. Eventually, it was recognized that
detecting all antibodies meant that significant amounts
of effort and time were expended,with little additional
benefit to the patient when providing timely, safe RBC
components. Methods were then adapted, reagents
developed, and practices changed that produced
improvement to the balance of detection of wanted
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Table 2. Method usage per College of American Pathologists Survey3,4
Laboratories reporting (%)
2001 2004 2005
Saline 3 2 2
BS Albumin 9 6 5
LISS 48 40 37
PEG 9 7 8
Gel 26 42 45
SPRCA 4 2 2
Liquid microwell 0.6 0.5 0.2
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and unwanted antibodies. Questions still remain today
about the true relevance of some results that are found
in testing. Deciding the relevance of what is found
relies on the reputation of the serologic specificity
without foundation or costly, time-consuming testing to
prove the prediction of in vivo RBC destruction for the
example of the specificity identified in the patient.
The comparison of methods for sensitivity and for
specificity generally do not start from the same point.
Many studies are done retrospectively comparing two
different time periods. Other studies compare the new
test method with what has been previously detected
by the predicate method.These types of studies are not
ideal because the cohort of stored samples is
inherently biased toward the method of original
detection. Ideally, prospective studies using consecu-
tive samples are best. Obtaining sufficient numbers of
samples is usually achievable for the specificity (true
antibody negative population) aspect of the study, but
obtaining enough samples to be able to demonstrate
statistical significance and breadth of reactivity of
specific antibodies for understanding the sensitivity of
the new test is another matter. Therefore, laboratories
and the manufacturers are left with the usual choice of
selecting previously positive, stored samples as the way
to evaluate sensitivity of the new test. This is a “one-
sided look at the coin” as there is no way to go back to
see if there was anything the existing method missed
that the new method would have caught. Unfortu-
nately, the ultimate correlation of these studies to in
vivo transfusion experience is rare.
This review focused on the comparison of the
newer technologies being used by both manual and
automated systems with each other and with current
commonly used tube methods. The studies that follow
show the variation in the sensitivity and specificity of
the various comparisons of test method performance
as well as the uniqueness of antibody reactivity
identified by specific methods.
In a study by Issitt et al. in 1997,13 1184 samples
were compared concurrently by PEG tube test and
SPRCA (Capture-R Ready Screen, ImmucorGamma)
methods.The data are presented in Table 3. Six percent
(67/1184) of the samples tested demonstrated
reactivity by the PEG tube test method while 11
percent (126/1184) demonstrated reactivity by SPRCA.
The PEG tube test detected 61 percent of the wanted
antibodies and 39 percent of the unwanted
specificities while SPRCA found 33 percent of wanted
and 67 percent of unwanted specificities.
In a study conducted in the same laboratory several
years later,14 a retrospective review of two different
years of testing, one in which the PEG test was used
and one in which the gel test (ID-MTS Gel Test, Ortho-
Clinical Diagnostics) was used, revealed the results
shown in Table 4. In this study, during the year in
which the PEG tube test was used, there were four
transfusion-related hemolytic events; one mechanical
or thermal-related, two with no assignable immune
cause, and one delayed hemolytic transfusion reaction
caused by anti-S. During that same time period,delayed
serologic transfusion reactions (DSTR) were also
evaluated. There were 21 missed antibodies (4 anti-E, 3
anti-c, 3 anti-Jka, 3 anti-Fya, 2 anti-Jkb, 2 anti-D, 1 anti-c,E,
and 1 anti-E, -Jkb) in 19 patients with DSTR. In the year
of testing using the gel test, there were no transfusion-
related hemolytic events;however 9 patients had DSTR
with 11 missed antibodies (3 anti-K, 2 anti-c, 2 anti-E,
-Fya, 1 anti-D, and 1 anti-Jka).
A more recent study15 (Table 5) comparing gel (ID-
MTS Gel, Ortho-Clinical Diagnostics) and SPRCA
(Capture-R Ready Screen, ImmucorGamma) with a new
indicator RBC coated with a different source of
antibody directed at the Fc portion of anti-IgG
compared two study time periods. There was a 2.3
percent higher reactive rate in SPRCA testing as
compared with that using gel. The wanted antibody
detection rates were similar. Overall, 4.2 percent of




positive positive by Specificity of
samples by method method antibody detected
PEG + 14 67 6% 2 anti-Lea, 5 false positive,
SPRCA – 3 benign autoantibodies,
2 anti-D, 2 anti-E
PEG + 53 4 insignificant,
SPRCA + 5 falsepositive,
7 benign autoantibodies,
37 significant
PEG – 73 126 11% 0 insignificant,
SPRCA + 46 false positive,
22 benign autoantibodies,
1 anti-D, 1 anti-c, 1 anti-K,
2 anti-Jka




Method samples w/Abs AbSc + Wanted Unwanted
PEG 37,832 3085 8% 71% 29%
Gel 43,405 2715 6% 80% 20%
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patient samples tested by SPRCA had unwanted
antibodies detected while 2.0 percent of patient
samples tested by gel had unwanted antibodies
detected. Fourteen percent of samples from D–
obstetrical patients demonstrated passive anti-D by the
gel test while 42 percent were reactive by SPRCA.
Eliminating the detection of antenatal Rh
immunoglobulin as an unwanted antibody reduced the
unwanted rate to 0.5 percent for gel and 1.4 percent
for SPRCA.
In a study comparing SPRCA from different
manufacturers, 934 samples were tested using Capture-
R Ready Screen (ImmucorGamma) and Solidscreen II
(Biotest).16 This comparison demonstrates similarity in
sensitivity and only minor differences in specificity
(Table 6).
In a study17 that evaluated quantitative concen-
tration of antibody using various test methods, known
concentrations of Anti-D were tested using the same
RBC (R2R2) by LISS-additive, PEG, and gel test methods.
The lowest detectable level for both PEG and gel test
methods was 5 ng/mL, while the lowest for the LISS-
additive method was 11 ng/mL.
Method-Dependent Antibodies
All methods of antibody detection have found
some antibodies that fall into the category of being
method-dependent antibodies. Method-dependent in
this author’s opinion indicates antibodies that are
usually found by only one method. With the
introduction of the newer methods, these method-
dependent antibodies might be detectable with a
second method but are undetectable by all other
methods.
In early studies of the effects of low-ionic solution
versus normal ionic solution, 195 serums that
contained an example of anti-K were studied. Of these,
189 were detected by both normal and low-ionic
strength solution test methods, 2 were detected only
by the normal ionic strength solution test, and 4
examples were detected only by the low-ionic strength
solution test.18
Issitt et al.19 reported on the testing of 10,000
patient samples that were all initially determined to be
negative for antibodies using a LISS-based test method.
These patients were transfused, if required,with blood
found to be compatible by the immediate spin
crossmatch method used in their transfusion service.
All 10,000 samples were subsequently tested using an
enzyme-treated antibody screen test method. Thirty-six
examples of enzyme-dependent antibodies in the Rh
blood group system were found. Retrospective antigen
typing of each of the units transfused to these patients
was performed to determine which units were given to
patients with the corresponding antibody identified by
the enzyme test method. Of 19 patients receiving
antigen positive units, 18 had no evidence of a
transfusion reaction and had no change in their
antibody’s serologic reactivity. One patient whose
sample demonstrated an anti-c had a delayed hemolytic
transfusion reaction. In addition to the Rh antibodies
of potential significance, 28 examples of clinically
insignificant antibodies based on specificity and 216
cold benign autoantibodies were detected using the
enzyme antibody screen test.
Additional studies20 of 29 LISS-negative, ficin-
positive Rh antibodies demonstrated discordant results
with other test methods. Nine of 25 of these antibodies
tested by polybrene showed reactivity while 11 of 27
reacted by the PEG test method.
In studies by Contreras et al.,21 14 percent of 218
examples of anti-E were only detected using enzyme-
treated screen RBCs; 21 percent of the 218 examples
were from patients who were never transfused. In the
same study, 61 examples of anti-D were detected in
23,000 obstetrical patient samples by the manual
polybrene method only. The titer of these antibodies
did not change throughout the pregnancy despite the
fetuses being D+.
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Table 5. Comparison of testing with gel and SPRCA15
Metric Gel SPRCA Statistical data
Study period 5.5 wks 24.5 wks
# Antibody screen tests 2400 10,400
Reactive rate 4.4% 6.7% P<0.0001
Wanted antibodies 2.4% 2.5%
Nonspecific antibodies 0.2% 0.9% P<0.001
Warm autoantibodies 0.2% 0.3% P<0.05 by 95%CI
Cold agglutinins 0.1% 0.2% P<0.05 by 95%CI
Antenatal RhIG 14% (1.5%) 42% (2.8%) P<0.0001
Table 6. Comparison of two SPRCA methods16
Metric Capture-R Ready Screen Solidscreen
# Antibody screens tests 934 934
# Reactive 35 29
Wanted antibodies 18 18
Unwanted antibodies 1 4
False positive* 16 11
Specificity 98.8% 98.3%
*False positive results were not defined
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These examples of method-dependent antibodies
appear for the most part to be of no clinical
importance;however there is another“side of the coin”
to consider. The following represent a few of the
sporadic,more recent reports of such antibodies found
in the literature or through anecdotal reports.
Callahan et al.22 had a patient sample in which they
found only the presence of anti-E, despite testing with
PEG and LISS-additive methods. Chronic transfusion of
this patient with E– units found repetitive transfusion
reactions with clinical hemolysis,yet with no additional
detectable antibody. Upon encountering a severe
reaction, further studies using SPRCA found anti-Jkb.
This antibody was not detectable in LISS, PEG, saline
tube methods, or gel. Days later this antibody was still
only detectable by SPRCA.
Barker et al.23 reported on a patient whose serum
was negative when tested by LISS tube method, but
who, when transfused, had a delayed transfusion
reaction. The pretransfusion sample was retro-
spectively tested by LISS,PEG,and gel tests, all of which
were negative. The posttransfusion sample demon-
strated reactivity by PEG only and anti-Fya was
identified. Approximately one week later, all three
methods demonstrated anti-Fya reactivity.
Discussion
Generally,most of the tube methods and automated
test methods currently in use have comparable
sensitivity and specificity. The selection of the test
method for routine antibody screening and
identification should be based on the balance of
sensitivity and specificity (relevance). One should
consider the time, resources, and cost of those test
methods that can detect high numbers of unwanted
antibodies along with the potential impact of these
factors on patient treatment. One must consider
alternative approaches to routine methods or
alternative methods of testing when clinical
manifestations of problems occur that point to
transfusion-related hemolytic events. The other
consideration is that any routine method could
produce unique unexpected reactivity that may have
no clinical relevance; an alternate method may be
required to avoid this type of reactivity.
The old adage that “no one method will detect all
antibodies of clinical importance” is no different today
in antibody detection methods using newer
technologies in manual and automated systems than it
was in tube test methods that transfusion services have
used for the past 50 years.The uncontrollable variables
that affect antigen-antibody reaction have not changed.
The consideration that a test is “perfect”will leave one
with the false sense of security that by using a single
test method, all clinically significant antibodies will be
detected. It is likely that every transfusion medicine
professional will encounter at least one unpreventable
delayed hemolytic transfusion reaction of significant
consequences and several delayed serologic
transfusion reactions in his or her career.
As Peter Issitt so eloquently articulated in a
previous article in this journal,24 “It is apparent that the
next major advance for in vitro testing will be related
to a forecast of the antibody’s in vivo behavior and not
the in vitro sensitivity of the method.”
The search for the “Holy Grail” of RBC antibody
screening continues . . .
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